DR. SURABHI PRIYADARSHINI

DR. ARCHANA SINHA, DR. MD. RAGHIB TAUHEED, DR. NEHA KIRAN

Abstract

Purpose: To observe the role of Ripasudil (0.4%) eye drops as adjunct therapy in IOP reduction and it’s safety profile in secondary glaucomas.

Method: 42 eyes of 27 patients (15 females and 12 males) having secondary glaucomas were started on Ripasudil (0.4%) eye drops as an adjunct to their anti glaucoma therapy. They were followed up every biweekly for 4 months and were observed for mean IOP reduction and development of any adverse reaction.

Result: Mean age of the patients was 31.3+/- 2.6 years. 12 eyes had post keratoplasty glaucoma, 18 eyes had steroid induced glaucoma, 7 eyes had uveitic glaucoma and 5 eyes had exfoliation glaucoma. Mean pre treatment IOP of the group was 26.32 +/- 2.1 mm hg. Mean IOP reduction at 4th month was 5.97 +/- 1.28 mm hg. 8 patients (19.04%) reported conjunctival hyperaemia and 1 patient (2.3%) reported blepharitis. No systemic adverse reaction was observed.

Conclusion: Ripasudil (0.4%) eye drops can be used as an adjunct therapy in secondary glaucomas.